Understanding how chromosomal instability affects the severity of prostate cancer
Investigating the impact of chromosomal instability on prostate cancer aggressiveness
This study is looking at how certain changes in chromosomes might make prostate cancer more aggressive, and it's for men with prostate cancer who want to learn about new ways to treat their condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10993877 on NIH RePORTER |
What this research studies
This research investigates the role of chromosomal instability (CIN) in the aggressiveness of prostate cancer, a leading cause of cancer-related deaths in men. By utilizing advanced techniques such as genetic analysis, proteomics, and high-resolution microscopy, the study aims to uncover the molecular mechanisms linking CIN to the survival and adaptation of prostate cancer cells. The researchers will focus on the role of MASTL kinase in regulating processes that may contribute to cancer progression and immune response. Patients may benefit from insights that could lead to new therapeutic strategies targeting aggressive prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic prostate cancer exhibiting high levels of chromosomal instability.
Not a fit: Patients with early-stage prostate cancer or those without chromosomal instability may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with aggressive prostate cancer.
How similar studies have performed: Previous research has shown that targeting chromosomal instability in cancer can lead to significant advancements in treatment, suggesting potential success for this approach.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Rodriguez-Bravo, Veronica — Mayo Clinic Rochester
- Study coordinator: Rodriguez-Bravo, Veronica
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.